Table 2 Efficacy of preoperative afatinib versus no treatment on CT scan/MRI according to RECIST1.1 and FDG-PET scan according to PERCIST.

From: Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity

n (%)

CT scan/MRI

FDG-PET scan

Arm A (N = 41)

Arm B (N = 18)

Arm A (N = 41)

Arm B (N = 18)

PR

3 (7.3%)

0

24 (58.5%)

0

SD

34 (82.9%)

14 (77.7%)

14 (34.1%)

13 (72.2%)

PD

0

3 (16.6%)

1 (2.4%)

3 (16.7%)

Non-evaluable

4 (9.8%)

1 (5.7%)

2 (5.0%)

2 (11.1%)

P-value

0.03

 < 0.01

  1. SD stable disease, PD progressive disease, PR partial response.
  2. Significant values are in bold.
Back to article page